{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:32:42Z","timestamp":1784241162049,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The evidence supporting an initial mycophenolate mofetil (MMF) dose of 2\u00a0g daily in tacrolimus-treated renal transplant recipients is limited. In a non-contemporaneous single-centre cohort study we compared the incidence of leukopaenia, rejection and graft dysfunction in patients initiated on MMF 1.5\u00a0g and 2\u00a0g daily. Baseline characteristics and tacrolimus trough levels were similar by MMF group. MMF doses became equivalent between groups by 12-months post-transplant, driven by dose reductions in the 2\u00a0g group. Leukopaenia occurred in 42.4% of patients by 12-months post-transplant. MMF 2\u00a0g was associated with a 1.80-fold increased risk of leukopaenia compared to 1.5\u00a0g. Rejection occurred in 44.8% of patients by 12-months post-transplantation. MMF 2\u00a0g was associated with half the risk of rejection relative to MMF 1.5\u00a0g. Over the first 7-years post-transplantation there was no difference in renal function between groups. Additionally, the development of leukopaenia or rejection did not result in reduced renal function at 7-years post-transplant. Leukopaenia was not associated with an increased incidence of serious infections or rejection. This study demonstrates the initial MMF dose has implications for the incidence of leukopaenia and rejection. Since neither dose produced superior long-term graft function, clinical equipoise remains regarding the optimal initial mycophenolate dose in tacrolimus-treated renal transplant recipients.<\/jats:p>","DOI":"10.1038\/s41598-020-76379-6","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T11:05:02Z","timestamp":1604919902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function"],"prefix":"10.1038","volume":"10","author":[{"given":"Vatsa","family":"Dave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan R.","family":"Polkinghorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai Gene","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kanellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Mulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"76379_CR1","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg, H. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 357, 2562\u20132575. https:\/\/doi.org\/10.1056\/NEJMoa067411 (2007).","journal-title":"N. Engl. J. Med."},{"key":"76379_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","volume":"63","author":"P Halloran","year":"1997","unstructured":"Halloran, P. et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International mycophenolate mofetil renal transplant study groups. Transplantation 63, 39\u201347 (1997).","journal-title":"Transplantation"},{"key":"76379_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00007890-199202010-00031","volume":"53","author":"HW Sollinger","year":"1992","unstructured":"Sollinger, H. W., Deierhoi, M. H., Belzer, F. O., Diethelm, A. G. & Kauffman, R. S. RS-61443\u2014A phase I clinical trial and pilot rescue study. Transplantation 53, 428\u2013432 (1992).","journal-title":"Transplantation"},{"key":"76379_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s004670050021","volume":"14","author":"G Filler","year":"2000","unstructured":"Filler, G., Zimmering, M. & Mai, I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr. Nephrol. 14, 100\u2013104 (2000).","journal-title":"Pediatr. Nephrol."},{"key":"76379_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00007691-200104000-00005","volume":"23","author":"T van Gelder","year":"2001","unstructured":"van Gelder, T., Klupp, J., Barten, M. J., Christians, U. & Morris, R. E. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monit. 23, 119\u2013128 (2001).","journal-title":"Ther. Drug Monit."},{"key":"76379_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0966-3274(97)80042-1","volume":"5","author":"K Zucker","year":"1997","unstructured":"Zucker, K. et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant. Immunol. 5, 225\u2013232 (1997).","journal-title":"Transplant. Immunol."},{"key":"76379_CR7","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1016\/j.transproceed.2005.07.033","volume":"37","author":"H Kocak","year":"2005","unstructured":"Kocak, H. et al. Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: Better 2-year graft and patient survival than with a higher mycophenolate mofetil dose. Transplant. Proc. 37, 3009\u20133011. https:\/\/doi.org\/10.1016\/j.transproceed.2005.07.033 (2005).","journal-title":"Transplant. Proc."},{"key":"76379_CR8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/0091270003256151","volume":"43","author":"DR Kuypers","year":"2003","unstructured":"Kuypers, D. R. et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: A prospective study in 100 de novo renal allograft recipients. J. Clin. Pharmacol. 43, 866\u2013880 (2003).","journal-title":"J. Clin. Pharmacol."},{"key":"76379_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00007890-200003150-00035","volume":"69","author":"J Miller","year":"2000","unstructured":"Miller, J., Mendez, R., Pirsch, J. D. & Jensik, S. C. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506\/MMF dose-ranging kidney transplant study group. Transplantation 69, 875\u2013880 (2000).","journal-title":"Transplantation"},{"key":"76379_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007890-200107150-00014","volume":"72","author":"JP Squifflet","year":"2001","unstructured":"Squifflet, J. P. et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 72, 63\u201369 (2001).","journal-title":"Transplantation"},{"key":"76379_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","volume":"88","author":"CE Staatz","year":"2014","unstructured":"Staatz, C. E. & Tett, S. E. Pharmacology and toxicology of mycophenolate in organ transplant recipients: An update. Arch. Toxicol. 88, 1351\u20131389. https:\/\/doi.org\/10.1007\/s00204-014-1247-1 (2014).","journal-title":"Arch. Toxicol."},{"key":"76379_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13037","author":"WR Mulley","year":"2017","unstructured":"Mulley, W. R. et al. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. Clin. Transplant. https:\/\/doi.org\/10.1111\/ctr.13037 (2017).","journal-title":"Clin. Transplant."},{"key":"76379_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/TP.0b013e31819389cc","volume":"87","author":"WR Mulley","year":"2009","unstructured":"Mulley, W. R. et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 87, 286\u2013289. https:\/\/doi.org\/10.1097\/TP.0b013e31819389cc (2009).","journal-title":"Transplantation"},{"key":"76379_CR14","volume-title":"Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model","author":"P Royston","year":"2011","unstructured":"Royston, P. & Lambert, P. C. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model (Stata Press, College Station, 2011)."},{"key":"76379_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 130, 461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002 (1999).","journal-title":"Ann. Intern. Med."},{"key":"76379_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006 (2009).","journal-title":"Ann. Intern. Med."},{"key":"76379_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.7326\/0003-4819-141-12-200412210-00009","volume":"141","author":"AD Rule","year":"2004","unstructured":"Rule, A. D. et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann. Intern. Med. 141, 929\u2013937. https:\/\/doi.org\/10.7326\/0003-4819-141-12-200412210-00009 (2004).","journal-title":"Ann. Intern. Med."},{"key":"76379_CR18","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1097\/TP.0000000000002762","volume":"103","author":"DK Metz","year":"2019","unstructured":"Metz, D. K. et al. Optimizing mycophenolic acid exposure in kidney transplant recipients: Time for target concentration intervention. Transplantation 103, 2012\u20132030. https:\/\/doi.org\/10.1097\/TP.0000000000002762 (2019).","journal-title":"Transplantation"},{"key":"76379_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12401","author":"C Ding","year":"2014","unstructured":"Ding, C. et al. Which is more suitable for kidney transplantation at the early post-transplantation phase in China\u2014Low dosing or standard dosing of enteric-coated mycophenolate sodium?. Int. J. Clin. Pract. Suppl. https:\/\/doi.org\/10.1111\/ijcp.12401 (2014).","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"76379_CR20","doi-asserted-by":"publisher","first-page":"E602","DOI":"10.1111\/ctr.12035","volume":"26","author":"C Doria","year":"2012","unstructured":"Doria, C. et al. Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: An analysis of the mycophenolic acid observational renal transplant registry. Clin. Transplant. 26, E602-611. https:\/\/doi.org\/10.1111\/ctr.12035 (2012).","journal-title":"Clin. Transplant."},{"key":"76379_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/j.1600-6143.2009.02668.x","volume":"9","author":"RS Gaston","year":"2009","unstructured":"Gaston, R. S. et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept trial. Am. J. Transplant. 9, 1607\u20131619. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02668.x (2009).","journal-title":"Am. J. Transplant."},{"key":"76379_CR22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","volume":"86","author":"T van Gelder","year":"2008","unstructured":"van Gelder, T. et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 86, 1043\u20131051. https:\/\/doi.org\/10.1097\/TP.0b013e318186f98a (2008).","journal-title":"Transplantation"},{"key":"76379_CR23","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2215\/CJN.09091209","volume":"5","author":"S Gourishankar","year":"2010","unstructured":"Gourishankar, S. et al. The CLEAR study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J. Am. Soc. Nephrol. 5, 1282\u20131289. https:\/\/doi.org\/10.2215\/CJN.09091209 (2010).","journal-title":"Clin J. Am. Soc. Nephrol."},{"key":"76379_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1097\/FTD.0b013e31826d7bfa","volume":"34","author":"BA Kiberd","year":"2012","unstructured":"Kiberd, B. A., Lawen, J. & Daley, C. Limits to intensified mycophenolate mofetil dosing in kidney transplantation. Ther. Drug Monit. 34, 736\u2013738. https:\/\/doi.org\/10.1097\/FTD.0b013e31826d7bfa (2012).","journal-title":"Ther. Drug Monit."},{"key":"76379_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/TP.0b013e31828c6dc7","volume":"96","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Controlled-dose versus fixed-dose mycophenolate mofetil for kidney transplant recipients: A systematic review and meta-analysis of randomized controlled trials. Transplantation 96, 361\u2013367. https:\/\/doi.org\/10.1097\/TP.0b013e31828c6dc7 (2013).","journal-title":"Transplantation"},{"key":"76379_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DR Kuypers","year":"2010","unstructured":"Kuypers, D. R. et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin. J. Am. Soc. Nephrol. 5, 341\u2013358. https:\/\/doi.org\/10.2215\/CJN.07111009 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"76379_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00467-015-3113-7","volume":"30","author":"R Becker-Cohen","year":"2015","unstructured":"Becker-Cohen, R. et al. Severe neutropenia in children after renal transplantation: Incidence, course, and treatment with granulocyte colony-stimulating factor. Pediatr. Nephrol. 30, 2029\u20132036. https:\/\/doi.org\/10.1007\/s00467-015-3113-7 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"76379_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1399-0012.2008.00893.x","volume":"22","author":"EL Hartmann","year":"2008","unstructured":"Hartmann, E. L. et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin. Transplant. 22, 822\u2013828. https:\/\/doi.org\/10.1111\/j.1399-0012.2008.00893.x (2008).","journal-title":"Clin. Transplant."},{"key":"76379_CR29","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","volume":"14","author":"GA Knoll","year":"2003","unstructured":"Knoll, G. A., MacDonald, I., Khan, A. & Van Walraven, C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J. Am. Soc. Nephrol. 14, 2381\u20132386 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"76379_CR30","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/j.1600-6143.2009.02699.x","volume":"9","author":"L Zafrani","year":"2009","unstructured":"Zafrani, L. et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am. J. Transplant. 9, 1816\u20131825. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02699.x (2009).","journal-title":"Am. J. Transplant."},{"key":"76379_CR31","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","volume":"355","author":"DC Brennan","year":"2006","unstructured":"Brennan, D. C. et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355, 1967\u20131977. https:\/\/doi.org\/10.1056\/NEJMoa060068 (2006).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76379-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:52:21Z","timestamp":1670367141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-76379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["76379"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-76379-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19379"}}